PINDAC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PINDAC (PINDAC).
Vasodilator (arteriolar dilator) reducing afterload; also inhibits platelet aggregation through inhibition of phosphodiesterase III.
| Metabolism | Hepatic via N-acetylation (polymorphic) and conjugation; active metabolite (hydralazine). |
| Excretion | Pindac (pindolol) is eliminated predominantly via hepatic metabolism (60-65%) with renal excretion of unchanged drug (35-40%). Less than 1% is excreted in feces via biliary elimination. |
| Half-life | Terminal elimination half-life is 3-4 hours in healthy individuals, prolonged to 7-15 hours in renal impairment and in elderly patients. Clinical context: dosing interval adjustment recommended for CrCl <30 mL/min. |
| Protein binding | 40-50% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | 2-3 L/kg (range 1.2-3.2 L/kg); high Vd indicates extensive tissue distribution, including crossing blood-brain barrier and placenta. |
| Bioavailability | Oral: 50-95% (mean ~85% with high first-pass metabolism; significant interindividual variation due to hepatic extraction). No data for other routes (IV is 100% by definition). |
| Onset of Action | Oral: 30-60 minutes for beta-blockade (reduction in heart rate); peak effect at 1-2 hours. Intravenous: within 1-5 minutes for acute effects. |
| Duration of Action | Oral: 12-24 hours (once-daily dosing for hypertension, but shorter for angina may require twice-daily). Clinical notes: intrinsic sympathomimetic activity may cause less bradycardia; duration of antihypertensive effect may last up to 24 hours with sustained-release formulation. |
| Molecular Weight | 285.34 |
Oral: 2.5-5 mg twice daily; maximum 20 mg daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: use every 24 hours;, not recommended if GFR <15 mL/min. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Start at 2.5 mg twice daily; increase cautiously due to age-related renal impairment. |
| 1st trimester | Avoid due to potential teratogenicity; limited human data. |
| 2nd trimester | Use only if benefit outweighs risk; monitor fetal growth. |
| 3rd trimester | Avoid near term due to risk of neonatal hypotension or other adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for PINDAC (PINDAC).
| Placental transfer | Crosses placenta in animal studies; human data limited. |
| Breastfeeding | Excretion into human milk is unknown; consider risk of infant exposure. Use with caution. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to pindacHistory of bronchial asthmaSevere bradycardiaCardiogenic shock
| Precautions | Drug-induced lupus (dose-related, more common in slow acetylators), peripheral neuritis (pyridoxine deficiency), hypotension, tachycardia, myocardial ischemia (in CAD), hepatotoxicity, hemolytic anemia (rare). |
| Food/Dietary | Avoid grapefruit juice during treatment with indacaterol as it may increase systemic exposure. No specific food interactions for pinaverium; however, high-fat meals may delay absorption. |
| Clinical Pearls |
Loading safety data…
| Teratogenic Risk | Pindolol (PINDAC) is a beta-blocker with FDA Pregnancy Category B. In the first trimester, data are limited but no consistent pattern of major malformations has been observed. However, beta-blockers may cause fetal bradycardia, hypoglycemia, and growth restriction, particularly in the second and third trimesters. Use should be limited to situations where benefit outweighs risk, with careful fetal monitoring. |
| Fetal Monitoring | Maternal: Blood pressure, heart rate, signs of heart failure or bronchospasm. Fetal: Heart rate monitoring, growth ultrasound (for intrauterine growth restriction), and assessment for neonatal bradycardia and hypoglycemia after delivery. |
| Fertility Effects | No specific studies on pindolol and human fertility. Beta-blockers may theoretically affect sperm function or ovulation but evidence is limited. Animal studies show no adverse effects on fertility. |
| PINDAC is a combination product containing indacaterol, a long-acting beta2-agonist (LABA), and pinaverium, an antispasmodic for irritable bowel syndrome (IBS). For asthma/COPD, monitor for paradoxical bronchospasm and cardiovascular effects. For IBS, caution in severe hepatic impairment. Indacaterol should not be used as rescue therapy; ensure patient has a short-acting bronchodilator available. |
| Patient Advice | Do not use PINDAC to relieve sudden breathing problems; always have your rescue inhaler with you. · If you experience chest pain, rapid heart rate, or worsening shortness of breath, seek medical attention immediately. · For IBS symptoms: take PINDAC exactly as prescribed; avoid crushing or chewing tablets. · Tell your doctor if you have high blood pressure, heart problems, liver disease, or glaucoma. · Common side effects include cough, headache, dry mouth, and constipation. |